Replies to post #154742 on Biotech Values

[mcbio]

This is a cancer trial mislabeled as an obesity trial. Talk of follow-on formulations, and the design of this study, appears to suggest this drug won't be used within the general population nor partnered for the obesity indication.

I certainly agree it's a rather strange trial. I guess they are hoping to kill two birds with one stone and see if there is both an effect on prostate cancer and an effect on weight loss? Perhaps if just an effect on weight loss they will move forward in just a general obese population?